Renalytix uses cookies to improve your experience. We respect your privacy and are committed to protecting your personal data. Read Privacy Notice

RenalytixAI CEO to Speak at the 40th Annual Cowen Health Care Conference

 

RenalytixAI CEO to Speak at the 40th Annual Cowen Health Care Conference

NEW YORK, March 2, 2020 /PRNewswire/ — Renalytix AI plc (AIM: RENX), a developer of artificial intelligence enabled clinical diagnostics for kidney disease, announces it will be presenting at the Cowen 40th Annual Health Care Conference taking place on March 1-4, 2020, at the Boston Marriott Copley Place in Boston, Massachusetts.

The conference brings together top institutional investors and leading companies operating in the Health Care space. James McCullough, CEO of RenalytixAI, will be presenting on Tuesday, March 3 at 8:40am – 9:10am EST in Dartmouth, located on the 3rd floor, breakout: Exeter, 3rd floor.

The presentation will be made available on the Company’s website shortly after, which can be located here: https://renalytixai.com/investors/company-presentation/. No new material or trading information will be provided.

About Kidney Disease 
Kidney disease is now recognized as a public health epidemic affecting over 850 million people globally. In the United States alone, over 40 million people are classified as having chronic kidney disease, with nearly 50 percent of individuals with advanced (Stage IV) disease unaware of the severity of their reduced kidney function. As a result, many patients progress to kidney failure in an unplanned manner, ending up having dialysis in the emergency room without ever seeing a clinical specialist, such as a nephrologist. Every day 13 patients die in the United States while waiting for a kidney transplant.

About RenalytixAI
RenalytixAI is a developer of artificial intelligence-enabled clinical diagnostic solutions for kidney disease, one of the most common and costly chronic medical conditions globally. The Company’s solutions are being designed to make significant improvements in kidney disease diagnosis and prognosis, clinical care, patient stratification for drug clinical trials, and drug target discovery. For more information, visit renalytixai.com.

SOURCE RenalytixAI

Help Me Spread The Post


If you enjoyed this post, we’d be grateful if you would help us spread its content.


Leave a comment

We’d love to hear your thoughts about this topic or any others. Please leave your comments below.

Note: your email address will not be published.






Well Filtered™

Get access to the blog, webinars and podcasts with the ideas, perspectives and innovations that matter most in kidney health.